Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 October 21, 2026 Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026 Read More October 20, 2026 Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test Read More August 4, 2026 Personalis Reports Second Quarter Results and Recent Highlights Read More July 20, 2026 Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform Read More July 14, 2026 Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain Read More June 9, 2026 Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits Read More June 2, 2026 Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026 Read More May 26, 2026 Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium Read More May 20, 2026 Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring Read More May 14, 2026 Personalis to Participate in Upcoming Investor Events Read More